Skip to main content
SpringerLink
Log in

Interferons 1992

How Much of the Promise Has Been Realised?

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Alexander GJM, Fagan EA, Daniels HM, Brahm J, Smith HM, et al. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 2: 66–68 1987

    PubMed  CAS  Google Scholar 

  • Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon-gamma. New England Journal of Medicine 322: 16–21 1990

    PubMed  CAS  Google Scholar 

  • Balkwill FR. Interferons. Lancet 1: 1060–1063 1989

    PubMed  CAS  Google Scholar 

  • Bermudez LEM, Young LS. Tumor necrosis factor, alone or in combination with interleukin-2 but not interferon-gamma, is associated with macrophage killing of Mycobacterium avium complex. Journal of Immunology 140: 3006–3013 1988

    CAS  Google Scholar 

  • Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. New England Journal of Medicine 320: 1731–1735 1989

    PubMed  CAS  Google Scholar 

  • Boguniewicz M, Jaffe HS, Izu A, Sullivan MJ, York D, et al. Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. American Journal of Medicine 88: 365–370, 1999

    Google Scholar 

  • Boraschi D, Censini S, Tagliabue A. Interferon-gamma reduces macrophage-suppressive activity by inhibiting PGE2 release and inducing interleukin-1 production. Journal of Immunology 133: 764–768 1984

    CAS  Google Scholar 

  • Borden EC. Effects of interferons in neoplastic diseases of man. Pharmacology and Therapeutics 37: 213–229 1988

    PubMed  CAS  Google Scholar 

  • Borden EC, Ball LA. Interferons: biochemical, cell growth inhibitory, and immunological effects. Progress in Hematology 12: 299–339 1981

    PubMed  CAS  Google Scholar 

  • Byrne GI, Lehmann LK, Landry GJ. Induction of tryptophan catabolism is the mechanism of gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infection and Immunity 53: 347–351 1986

    PubMed  CAS  Google Scholar 

  • Carlin JM, Borden EC, Sondel PM, Byrne GI. Biological response modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. Journal of Immunology 139: 2414–2418 1987

    CAS  Google Scholar 

  • Carvalho EM, Badaro R, Reed SG, Jones TC, Johnson Jr WD. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. Journal of Clinical Investigation 76: 2066–2069 1985

    PubMed  CAS  Google Scholar 

  • Castilla A, Prieto J, Fausto N. Transforming growth factors beta I and alpha in chronic liver disease. New England Journal of Medicine 324: 933–940 1991

    PubMed  CAS  Google Scholar 

  • Chen L, Tourvielle B, Burns GF, Bach FH, Mathieu-Mahul D, et al. Interferon: a cytotoxic T lymphocyte differentiation signal. European Journal of Immunology 16: 767–770 1986

    PubMed  CAS  Google Scholar 

  • Cohen MC, Huberman MS, Nesto RW. Recombinant alpha-2-interferon related cardiomyopathy. American Journal of Medicine 85: 549–551 1988

    PubMed  CAS  Google Scholar 

  • Crane Jr JL, Glasgow LA, Kern ER, Youngner JS. Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon. Journal of the National Cancer Institute 61: 871–874 1978

    PubMed  Google Scholar 

  • Davis GL, Baiart LA, Schiff ER, Lindsay K, Bodenheimer HC, et al. (The Hepatitis Interventional Therapy Group). Treatment of chronic hepatitis C with recombinant interferon alpha. New England Journal of Medicine 321: 1501–1506 1989

    PubMed  CAS  Google Scholar 

  • Del Prete G, Tiri A, Maggi E, De Carli M, Macchia D, et al. Defective in vitro production of gamma-interferon and tumor necrosis factor-alpha by circulating T cells from patients with the hyper-immunoglobulin E syndrome. Journal of Clinical Investigation 84: 1830–1835 1989

    PubMed  Google Scholar 

  • de Wit R, Boucher CAB, Veenhof KHN, Schattenkerk JKME, Bakker PJM, et al. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi’s sarcoma. Lancet 2: 1214–1217 1988

    PubMed  Google Scholar 

  • Deyton LR, Walker RE, Kovacs JA, Herpin B, Parker M, et al. Reversible cardiac dysfunction associated with interferon alpha therapy in AIDS patients with Kaposi’s sarcoma. New England Journal of Medicine 321: 1246–1249 1989

    PubMed  CAS  Google Scholar 

  • Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, et al. Recombinant interferon alpha therapy for chronic hepatitis C. New England Journal of Medicine 321: 1506–1510, 1989

    PubMed  Google Scholar 

  • Dinauer MC, Orkin SH. Molecular genetics of chronic granulomatous disease. Immunodeficiency Reviews 1: 55–69, 1988

    PubMed  CAS  Google Scholar 

  • Douglas Jr JM, Eron LJ, Judson FN, Rogers M, Alder MB, et al. A randomized trial of combination therapy with intralesional interferon alpha 2b and podophyllin versus podophyllin alone for the therapy of anogenital warts. Journal of Infectious Diseases 162: 52–59, 1990

    PubMed  Google Scholar 

  • Douglas RM, Moore BW, Miles HB, Davies LM, Graham NMH, et al. Prophylactic efficacy of intranasal alpha2-interferon against rhinovirus infections in the family setting. New England Journal of Medicine 314: 65–70, 1986

    PubMed  CAS  Google Scholar 

  • Douvas GS, Looker DL, Vatter AE, Crowle AJ. Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infection and Immunity 50: 1–8, 1985

    PubMed  CAS  Google Scholar 

  • Dusheiko G, Di Bisceglie A, Bowyer S, Sachs E, Ritchie M, et al. Recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology 5: 556–560, 1985

    PubMed  CAS  Google Scholar 

  • Editorial. Hepatitis treatment by Schering-Plough gets FDA approval. Wall Street Journal, February 26, 1991

  • Edwards L, Levine N, Weidner M, Piepkorn M, Smiles K. Effect of intralesional alpha2-interferon on actinic keratoses. Archives of Dermatology 122: 779–782, 1986

    PubMed  CAS  Google Scholar 

  • Edwards L, Tucker SB, Perednia D, Smiles KA, Taylor EL, et al. The effect of an intralesional sustained-release formulation of interferon-alpha-2b on basal cell carcinomas. Archives of Dermatology 126: 1029–1032, 1990

    PubMed  CAS  Google Scholar 

  • Fellous M, Kamoun M, Gresser I, Bono R. Enhanced expression of HLA antigens and beta2-microglobulin on interferon-treated human lymphoid cells. European Journal of Immunology 9: 446–449, 1979

    PubMed  CAS  Google Scholar 

  • Finkelman FD, Holmes J, Katona IM, Urban Jr JF, Beckmann MP, et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annual Review of Immunology 8: 303–333, 1990

    PubMed  CAS  Google Scholar 

  • Finter NB, Chapman S, Dowd P, Johnston JM, Manna V, et al. The use of interferon-α in virus infections. Drugs 42: 749–765, 1991

    PubMed  CAS  Google Scholar 

  • Foon KA, Bottino GC, Abrams PG, Fer MF, Longo DL, et al. Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. American Journal of Medicine 78: 216–220, 1985

    PubMed  CAS  Google Scholar 

  • Fossa SD, Lien HH, Lindegaard M. Effect of recombinant interferon alpha on bone metastases of renal-cell carcinoma. New England Journal of Medicine 324: 633–634, 1991a

    PubMed  CAS  Google Scholar 

  • Fossa SD, Stenwig AE, Lien HH. Long-term results in patients with metastatic renal cell carcinoma treated with interferon with or without vinblastine. World Journal of Urology, in press, 1991b

    Google Scholar 

  • Gallin JI; Malech HL, Weening RS, Curnette JT, Quie PG, et al. (The International Chronic Granulomatous Disease Cooperative Study Group). A controlled trial of interferon-gamma to prevent infection in chronic granulomatous disease. New England Journal of Medicine 324: 509–516, 1991

    Google Scholar 

  • Gallin JI, Sechler JMG, Malech HL. Reconstitution of defective phagocyte function in chronic granulomatous disease of childhood with recombinant human interferon-gamma. Transactions of the Association of American Physicians 101: 12–17, 1988

    PubMed  CAS  Google Scholar 

  • Gauchat J-F, Lebman DA, Coffman RL, Gascan H, de Vries JE. Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production. Journal of Experimental Medicine 172: 463–473, 1990

    PubMed  CAS  Google Scholar 

  • Goldstein D, Laszlo J. Interferon therapy in cancer: from imaginon to interferon. Cancer Research 46: 4315–4329, 1986

    PubMed  CAS  Google Scholar 

  • Greenway Jr HT, Cornell RC. Interferon: coming of age. Archives of Dermatology 126: 1080–1082, 1990

    PubMed  Google Scholar 

  • Greenway Jr HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, et al. Treatment of basal cell carcinoma with intralesional interferon. Journal of the American Academy of Dermatology 15: 437–443, 1986

    PubMed  CAS  Google Scholar 

  • Hayden FG, Albrecht JK, Kaiser DL, Gwaltney Jr JM. Prevention of natural colds by contact prophylaxis with intranasal alpha2-interferon. New England Journal of Medicine 314: 71–75, 1986

    PubMed  CAS  Google Scholar 

  • Herberman RB, Ortaldo JR, Mantovani A, Hobbs DS, Kung H-F, et al. Effect of human recombinant interferon on cytotoxic activity of natural killer cells and monocytes. Cellular Immunology 67: 160–167, 1982

    PubMed  CAS  Google Scholar 

  • Heron I, Berg K, Cantell K. Regulatory effect of interferon on T cells in vitro. Journal of Immunology 117: 1370–1373, 1976

    CAS  Google Scholar 

  • Hirsch MS, Schooley RT, Cosimi AB, Russell PS, Delmonico FL, et al. Effects of interferon-alpha on cytomegalovirus reactivation syndrome in renal-transplant recipients. New England Journal of Medicine 308: 1489–1493, 1983

    PubMed  CAS  Google Scholar 

  • Ho DD, Rota TR, Kaplan JC, Hartshorn KL, Andrews CA, et al. Recombinant human interferon alpha-A suppresses HTLV-III replication in vitro. Lancet 1: 602–604, 1985

    PubMed  CAS  Google Scholar 

  • Hoffnagle JH, Mullen K, Peters M, Avigan M, Park Y, et al. Treatment of chronic delta hepatitis with recombinant human alpha interferon. Progress in Clinical and Biological Research 234: 291–298, 1987

    Google Scholar 

  • Horning SJ, Merigan TC, Krown SE, Gutterman JU, Louie A, et al. Human interferon alpha in malignant lymphoma and Hodgkin’s disease: results of the American Cancer Society trial. Cancer 56: 1305–14310, 1985

    PubMed  CAS  Google Scholar 

  • Hugli TE. Chemotaxis. Current Opinion in Immunology 2: 19–27, 1989

    PubMed  CAS  Google Scholar 

  • Isaacs A, Lindemann J. Virus interference. I. The interferon. Proceedings of the Royal Society of London 147: 258–267, 1957

    PubMed  CAS  Google Scholar 

  • Jacobs AD, Champlin RE, Golde DW. Recombinant alpha-2-interferon for hairy cell leukemia. Blood 65: 1017–1020, 1985

    PubMed  CAS  Google Scholar 

  • Kahan A, Amor B, Menkes CJ, Strauch G. Recombinant interferon-gamma in the treatment of systemic sclerosis. American Journal of Medicine 87: 273–277, 1989

    PubMed  CAS  Google Scholar 

  • Katz P, Yeager Jr H, Whalen G, Evans M, Swartz RP, et al. Natural killer cell-mediated lysis of Mycobacterium avium complex-infected monocytes. Journal of Clinical Immunology 10: 71–77, 1990

    PubMed  CAS  Google Scholar 

  • Kawabe T, Takami M, Hosoda M, Maeda Y, Sato S, et al. Regulation of Fc epsilon R2/CD23 gene expression by cytokines and specific ligands (IgE and anti-Fc epsilon R2 monoclonal antibody): variable regulation depending on the cell types. Journal of Immunology 141: 1376–1382, 1988

    CAS  Google Scholar 

  • King CL, Ottesen EA, Nutman TB. Cytokine regulation of antigen-driven immunoglobulin production in filarial parasite infections in humans. Journal of Clinical Investigation 85: 1810–1815, 1990

    PubMed  CAS  Google Scholar 

  • Kovacs JA, Deyton L, Davey R, Falloon J, Zunich K, et al. Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome. Annals of Internal Medicine 111; 280–287, 1989

    PubMed  CAS  Google Scholar 

  • Krim M. Towards tumor therapy with interferons. Part II. Interferons: in vivo effects. Blood 55: 875–884, 1980

    PubMed  CAS  Google Scholar 

  • Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, et al. Interferon-alpha in patients witha symptomatic human immunodeficiency virus (HIV) infection. Annals of Internal Medicine 112: 805–811, 1990

    PubMed  CAS  Google Scholar 

  • Lane HC, Feinberg J, Davey V, Deyton L, Baseler M, et al. Antiretroviral effects of interferon-alpha in AIDS-associated Kaposi’s sarcoma. Lancet 2: 1218–1222, 1988

    PubMed  CAS  Google Scholar 

  • Langer JA, Pestka S. Interferon receptors. Immunology Today 9: 393–400, 1988

    PubMed  CAS  Google Scholar 

  • Lappin DF, Bimie GD, Whaley K. Modulation by interferons of the expression of monocyte complement genes. Biochemical Journal 268: 387–392 1990

    PubMed  CAS  Google Scholar 

  • Le J, Yip YK, Vilcek J. Cytolytic activity of interferon-gamma and its synergism with 5-fluorouracil. International Journal of Cancer 34: 495–500 1984

    CAS  Google Scholar 

  • Leeuwenberg JFM, Von Asmuth EJU, Jeunhomme TMAA, Buurman WA. Interferon-gamma regulates the expression of the adhesion molecule ELAM-1 and IL-6 production by human endothelial cells in vitro. Journal of Immunology 145: 2110–2114 1990

    CAS  Google Scholar 

  • Li JTC, Yunginger JW, Reed CE, Jaffe HS, Nelson DR, et al. Lack of suppression of IgE production by recombinant interferon gamma: a controlled trial in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology 85: 934–940 1990

    PubMed  CAS  Google Scholar 

  • MacKie RM. Interferon-α for atopic dermatitis. Lancet 335: 1282–1283 1990

    PubMed  CAS  Google Scholar 

  • Maggie E, Del Prete GF, Parronchi P, Tiri A, Macchia D, et al. Role for T cells, IL-2 and IL-6 in the 14-dependent in vitro human IgE synthesis. Immunology 68: 300–306 1989

    Google Scholar 

  • Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, et al. Maintenance treatment with recombinant interferon alpha-2B in patients with multiple myeloma responding to conventional induction chemotherapy. New England Journal of Medicine 322: 1430–1434 1990

    PubMed  CAS  Google Scholar 

  • Maziarz RT, Tepler I, Antin JH, Keroack MA, Churchill WH, et al. Reversal of infection with Mycobacterium avium intracellulare by treatment with alpha-interferon in a patient with hairy cell leukemia. Annals of Internal Medicine 109: 292–294 1988

    PubMed  CAS  Google Scholar 

  • Merigan TC. Interferon inducers revisited. New England Journal of Medicine 291: 95–96 1974

    Google Scholar 

  • Merigan TC. Present approval of and future hopes for the clinical utilization of human interferons. Interferon 3: 135–154 1981

    Google Scholar 

  • Merigan TC, Rand KH, Pollard RB, Abdallah PS, Jordan GW, et al. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. New England Journal of Medicine 298: 981–987 1978a

    PubMed  CAS  Google Scholar 

  • Merigan TC, Sikora K, Breeden JH, Levy R, Rosenberg SA. Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. New England Journal of Medicine 299: 1449–1453 1978b

    PubMed  CAS  Google Scholar 

  • Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47: 207–214 1981

    PubMed  CAS  Google Scholar 

  • Monto AS, Schwartz SA, Albrecht JK. Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families. Antimicrobial Agents and Chemotherapy 33: 387–390 1989

    PubMed  CAS  Google Scholar 

  • Morikawa K, Fidler IJ. Heterogeneous response of human colon cancer cells to the cytostatic and cytotoxic effects of recombinant human cytokines: interferon-alpha, interferon-gamma, tumor necrosis factor, and interleukin-2. Journal of Biological Response Modifiers 8: 206–218 1989

    PubMed  CAS  Google Scholar 

  • Murray HW, DePamphilis J, Schooley RT, Hirsch MS. Circulation interferon-gamma in AIDS patients treated with interleukin-2. New England Journal of Medicine 318: 1538–1539 1988a

    PubMed  CAS  Google Scholar 

  • Murray HW, Gellene RA, Libby DM, Rothermel CD. Rubin BY. Activation of tissue macrophages from AIDS patients: in vitro response of AIDS alveolar macrophages to lymphokines and interferon-gamma. Journal of Immunology 135: 2374–2377 1985

    CAS  Google Scholar 

  • Murray HW, Scavuzzo DA, Chaparas SD, Roberts RB. T lymphocyte responses to mycobacterial antigen in AIDS patients with disseminated Mycobacterium avium-Mycobacterium intracellulare infection. Chest 93: 922–925 1988b

    PubMed  CAS  Google Scholar 

  • Murray HW, Szuro-Sudol A, Wellner D, Oca MJ, Granger AM, et al. Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infection and Immunity 57: 845–849 1989

    PubMed  CAS  Google Scholar 

  • Nathan CF, Kaplan G, Levis WR, Nusrat A, Witmer MD, et al. Local and systemic effects of intradermal recombinant inter-feron-gamma in patients with lepromatous leprosy. New England Journal of Medicine 315: 6–15 1986

    PubMed  CAS  Google Scholar 

  • Nicolas J-F, Thivolet J. Interferon alpha therapy in severe unresponsive subacute cutaneous lupus erythematosus. New England Journal of Medicine 321: 1550–1551 1989

    PubMed  CAS  Google Scholar 

  • O’Connor BM, Clifford JS, Lawrence WD, Logue GL. Alpha-interferon for severe cold agglutinin disease. Annals of Internal Medicine 111: 255–256 1989

    PubMed  Google Scholar 

  • Panusarn C, Stanley ED, Dirda V, Rubenis M, Jackson GG. Prevention of illness from rhinovirus infection by a topical interferon inducer. New England Journal of Medicine 291: 57–61 1974

    PubMed  CAS  Google Scholar 

  • Pazin GJ, Armstrong JA, Lam MT, Tarr GC, Jannetta PJ, et al. Prevention of reactivated herpes simplex infection by human leukocyte interferon after operation on the trigeminal root. New England Journal of Medicine 301: 225–230m 1979

    PubMed  CAS  Google Scholar 

  • Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Lindsay K, et al. (The Hepatitis Interventional Therapy Group). A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. New England Journal of Medicine 323: 295–301 1990

    PubMed  CAS  Google Scholar 

  • Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annual Review of Biochemistry 56: 727–777 1987

    PubMed  CAS  Google Scholar 

  • Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS. Interferon-alpha but not AZT suppresses HIV expression in a chronically infected cell line. Science 244: 575–577 1989

    PubMed  CAS  Google Scholar 

  • Quesada JR, Reuben J, Manning JT, Hersh EM, Hutterman JU. Alpha-interferon for induction of remission in hairy-cell leukemia. New England Journal of Medicine 310: 15–18 1984

    PubMed  CAS  Google Scholar 

  • Reiner NE, Ng JW, Wilson CB, McMaster WR, Burchett SK. Modulation of in vitro monocyte cytokine responses to Leishmania donovani. Journal of Clinical Investigation 85: 1914–1924 1990

    PubMed  CAS  Google Scholar 

  • Reinhold U, Wehrmann W, Kukel S, Kreysel H-W. Recombinant interferon-7 in severe atopic dermatitis. Lancet 335: 1282, 1990

    PubMed  CAS  Google Scholar 

  • Ritz J. The role of natural killer cells in immune surveillance. New England Journal of Medicine 320: 1748–1749 1989

    PubMed  CAS  Google Scholar 

  • Romagnani S. Regulation and deregulation of human IgE synthesis. Immunology Today 11: 316–321 1990

    PubMed  CAS  Google Scholar 

  • Rook GAW, Steele J, Fraher L, Barker S, Karmali R, et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57: 159–163 1986

    PubMed  CAS  Google Scholar 

  • Salvin SB, Youngner JS, Nishio J, Neta R. Brief communication: tumor suppression by a lymphokine released into the circulation of mice with delayed hypersensitivity. Journal of the National Cancer Institute 55: 1233–1234 1975

    PubMed  CAS  Google Scholar 

  • Schultz RM. Macrophage activation by interferons. Lymphokine Reports 1: 63–97 1980

    CAS  Google Scholar 

  • Scullard GH, Pollard RB, Smith JL, Sacks SL, Gregory PB, et al. Antiviral treatment of chronic hepatitis B virus infection. 1. Changes in viral markers with interferon combined with adenosine arabinoside. Journal of Infectious Diseases 143: 772–783 1981

    PubMed  CAS  Google Scholar 

  • Sen GC. Mechanisms of interferon action: progress toward its understanding. Progress in Nucleic Acid Research and Molecular Biology 27: 105–156 1982

    PubMed  CAS  Google Scholar 

  • Sherlock S, Thomas HC. Therapy of chronic hepatitis due to hepatitis B virus. Lancet 2: 1343–1346 1985

    PubMed  CAS  Google Scholar 

  • Sonnenfeld G. Modulation of immunity by interferon. Lymphokine Reports 1: 113–131 1980

    CAS  Google Scholar 

  • Souillet G, Rousset F, de Vries JE. Alpha-interferon treatment of patient with hyper IgE syndrome. Lancet 1: 1384, 1989

    PubMed  CAS  Google Scholar 

  • Squires KE, Murphy WF, Madoff LC, Murray HW. Interferongamma and Mycobacterium avium-intracellulare infection. Journal of Infectious Diseases 159: 599–600 1989

    PubMed  CAS  Google Scholar 

  • Stiehm ER, Kronenberg LH, Rosenblatt HM, Bryson Y, Merigan TC. Interferon: immunobiology and clinical significance. Annals of Internal Medicine 96: 80–93 1982

    PubMed  CAS  Google Scholar 

  • Stotter H, Wiebke EA, Tomita S, Belldegrun A, Topalian S, et al. Cytokines alter target cell susceptibility to lysis. Journal of Immunololgy 142: 1767–1773 1989

    CAS  Google Scholar 

  • Strander H. Interferon treatment of human neoplasms. Advances in Cancer Research 46: 1–203 1986

    PubMed  CAS  Google Scholar 

  • Suzuki Y, Conley FK, Remington JS. Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon. Infection and Immunity 58: 3050–3055 1990

    PubMed  CAS  Google Scholar 

  • Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, et al. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69: 1280–1288 1987

    PubMed  CAS  Google Scholar 

  • Testa U, Ferbus D, Gabbianelli M, Pascucci B, Boccoli G, et al. Effect of endogenous and exogenous interferons on the differentiation of human monocyte cell line U937. Cancer Research 48: 82–88 1988

    PubMed  CAS  Google Scholar 

  • Trinchieri G, Perussia B. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunololgy Today 6: 131–136 1985

    CAS  Google Scholar 

  • Turco J, Winkler HH. Gamma-interferon-induced inhibition on the growth of Rickettsia prowazekii in fibroblasts cannot be explained by the degradation of tryptophan or other amino acids. Infection and Immunity 53: 38–46 1986

    PubMed  CAS  Google Scholar 

  • Tyring S, Klimpel GR, Fleischmann Jr WR, Baron S. Direct cytolysis by partially purified preparations of immune interferons. International Journal of Cancer 30: 59–64 1982

    CAS  Google Scholar 

  • Vercelli D, Jabara HH, Lauener RP, Geha RS. IL-4 inhibits the synthesis of IFN-gamma and induces the synthesis of IgE in human mixed lymphocyte cultures. Journal of Immunology 144: 570–573 1990

    CAS  Google Scholar 

  • Wallach D, Fellous M, Revel M. Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNA in human cells. Nature 299: 833–836 1982

    PubMed  CAS  Google Scholar 

  • Weigent DA, Stanton J, Johnson HM. Recombinant gamma interferon enhances natural killer cell activity similar to natural gamma interferon. Biochemical and Biophysical Research Communications 111: 525–529 1983

    PubMed  CAS  Google Scholar 

  • Ziegler-Heitbrock HWL, Schlag R, Flieger D, Thiel E. Favourable response of early stage B CLL patients to treatment with IFN-alpha2. Blood 73: 1426–1430 1989

    PubMed  CAS  Google Scholar 

  • Zielinski RM, Lawrence WD. Interferon-alpha for the hypereosinophilic syndrome. Annals of Internal Medicine 113: 716–718 1990

    PubMed  CAS  Google Scholar 

  • Zwingenberger K, Harms G, Pedrosa C, Omena S, Sandkamp B, et al. Determinants of the immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon-gamma production. Clinical Immunology and Immunopathology 57: 242–249 1990

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Conrad D. Stephenson Laboratory for Research in Immunology, Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, Denver, USA

    Michael A. Volz & Charles H. Kirkpatrick

  2. University of Colorado Health Sciences Center, Denver, Colorado, USA

    Michael A. Volz & Charles H. Kirkpatrick

Authors
  1. Michael A. Volz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles H. Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Volz, M.A., Kirkpatrick, C.H. Interferons 1992. Drugs 43, 285–294 (1992). https://doi.org/10.2165/00003495-199243030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199243030-00001

Search

Navigation